KBC Group NV Has $53.11 Million Stake in Zoetis Inc. $ZTS

KBC Group NV increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 7.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 340,527 shares of the company’s stock after purchasing an additional 24,704 shares during the quarter. KBC Group NV’s holdings in Zoetis were worth $53,105,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. Nova Wealth Management Inc. bought a new position in Zoetis during the 1st quarter worth approximately $25,000. 1248 Management LLC bought a new stake in Zoetis in the 1st quarter valued at approximately $27,000. Saudi Central Bank acquired a new stake in Zoetis in the 1st quarter valued at $29,000. REAP Financial Group LLC boosted its position in Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares during the last quarter. Finally, NewSquare Capital LLC raised its position in Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Up 1.0%

Shares of ZTS opened at $121.30 on Thursday. The stock’s 50-day moving average price is $142.21 and its two-hundred day moving average price is $151.94. Zoetis Inc. has a 12 month low of $117.26 and a 12 month high of $181.85. The company has a market capitalization of $53.45 billion, a PE ratio of 20.88, a PEG ratio of 2.31 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the previous year, the business earned $1.58 earnings per share. Zoetis’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is 33.67%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Argus reissued a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. JPMorgan Chase & Co. dropped their price target on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, BTIG Research lowered their price objective on Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a research note on Wednesday. Six equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Moderate Buy” and a consensus price target of $180.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.